title: [Clinical value of the use of magnesium orotate in adolescents with syndrome of cardiac connective tissue dysplasia].
abstract: According to results of clinical and instrumental investigation magnesium orotate (50 mg/day during first week and 25 mg/day thereafter) was found to be effective therapy of children with syndrome of cardiac connective tissue dysplasia (mainly with mitral valve prolapse and anomalous chordae tendineae).
authors.forename: T M
authors.initials: TM
authors.lastname: Domnitskaia
authors.forename: A V
authors.initials: AV
authors.lastname: D'iachenko
authors.forename: O O
authors.initials: OO
authors.lastname: Kupriianova
authors.forename: M V
authors.initials: MV
authors.lastname: Domnitskiĭ
mesh_terms: D000293:Adolescent; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D002815:Chordae Tendineae / Q000002:abnormalities; D003240:Connective Tissue Diseases / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008945:Mitral Valve Prolapse / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D009963:Orotic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012189:Retrospective Studies; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D009963:Orotic Acid; C104468:magnesium orotate